Details

Autor(en) / Beteiligte

• Ishitobi, Makoto
• Matsuda, Naoko
• Tazo, Mizuho
• Nakayama, Sayuka
• Tokui, Ryu
• Ogawa, Tomoko
• Yoshida, Atsushi
• Kojima, Yasuyuki
• Kuwayama, Takashi
• Nakayama, Takahiro
• Yamauchi, Hideko
• Nakamura, Seigo
• Tsugawa, Koichiro
• Hayashi, Naoki

Titel

Risk Factors for Ipsilateral Breast Tumor Recurrence in Triple-Negative or HER2-Positive Breast Cancer Patients Who Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy

Ist Teil von

• Annals of surgical oncology, 2021-05, Vol.28 (5), p.2545-2552

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2021

Quelle

SpringerLink Journals

Beschreibungen/Notizen

• Background Attention has been focused on attempts to eliminate breast surgery for breast cancer patients who achieve a pathologic complete response after neoadjuvant chemotherapy (NAC). However, there are few data on ipsilateral breast tumor recurrence (IBTR) among patients with triple-negative or epidermal growth factor receptor 2-positive (HER2+) tumors who achieve a pathologic complete response after NAC and breast-conserving treatment. Methods Using a multi-institutional retrospective database, this study evaluated the risk factors for IBTR among patients with newly diagnosed stages 1 to 3 breast cancer involving triple-negative or HER2+ tumors who achieved ypT0 after NAC and breast-conserving treatment. Results During a median follow-up period of 4.8 years (range, 0.1–15.5 years), the 5-year IBTR-free survival rate was 95.5%. The breast cancer subtype was not associated with IBTR-free survival. Patients younger than 40 years at diagnosis had significantly worse IBTR-free survival than those who were 40 years of age or older (5-year IBTR-free survival, 87.7 vs 96.9%; p  = 0.002). Conclusions This retrospective study demonstrated that age at diagnosis was independently associated with IBTR-free survival. Special caution is needed when clinical trials analyzing omission of breast surgery after NAC are enrolling younger patients (UMIN-CTR No. UMIN000037067).